CL2021001468A1 - Derivados esteroideos con actividad terapéutica - Google Patents
Derivados esteroideos con actividad terapéuticaInfo
- Publication number
- CL2021001468A1 CL2021001468A1 CL2021001468A CL2021001468A CL2021001468A1 CL 2021001468 A1 CL2021001468 A1 CL 2021001468A1 CL 2021001468 A CL2021001468 A CL 2021001468A CL 2021001468 A CL2021001468 A CL 2021001468A CL 2021001468 A1 CL2021001468 A1 CL 2021001468A1
- Authority
- CL
- Chile
- Prior art keywords
- therapeutic activity
- steroid derivatives
- disorders
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003270 steroid hormone Substances 0.000 abstract 2
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención se relaciona con compuestos de fórmula (I) y sus sales farmacéuticamente aceptables: (I) donde R1 a R4 corresponden a la definición de las reivindicaciones. La invención se relaciona además con su uso como inhibidores de 17ß- HSD1 y en el tratamiento o la prevención de enfermedades o trastornos dependientes de hormonas esteroideas, como enfermedades o trastornos dependientes de hormonas esteroideas que requieran la inhibición de la enzima 17ß-HSD1 y/o la reducción de la concentración de estradiol endógeno. La presente invención se relaciona además con la preparación de los compuestos mencionados y con composiciones farmacéuticas que comprende como ingredientes activos uno o más de los compuestos mencionados o sus sales farmacéuticamente aceptables
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20186056 | 2018-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001468A1 true CL2021001468A1 (es) | 2022-01-28 |
Family
ID=69005734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001468A CL2021001468A1 (es) | 2018-12-05 | 2021-06-03 | Derivados esteroideos con actividad terapéutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220041647A1 (es) |
| EP (1) | EP3891167A1 (es) |
| JP (1) | JP7417608B2 (es) |
| KR (1) | KR20210114390A (es) |
| CN (1) | CN113412269A (es) |
| AU (2) | AU2019393005B2 (es) |
| BR (1) | BR112021010598A2 (es) |
| CA (1) | CA3122049C (es) |
| CL (1) | CL2021001468A1 (es) |
| EA (1) | EA202191531A1 (es) |
| IL (1) | IL283588A (es) |
| MX (1) | MX2021006452A (es) |
| SG (1) | SG11202105795XA (es) |
| UA (1) | UA126881C2 (es) |
| WO (1) | WO2020115371A1 (es) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL343862A1 (en) | 1998-03-11 | 2001-09-10 | Endorech | Inhibitors of type 5 and type 3 17β−hydroxysteroid dehydrogenase and methods for their use |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| DK1423381T3 (da) | 2001-09-06 | 2007-05-07 | Schering Corp | 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme |
| AR036812A1 (es) | 2001-10-17 | 2004-10-06 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes |
| CA2506290C (en) | 2002-11-18 | 2012-04-24 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| JP4585320B2 (ja) | 2002-12-17 | 2010-11-24 | シェーリング コーポレイション | 男性ホルモン依存性疾患の処置のための１７β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター |
| WO2004085345A2 (en) | 2003-03-21 | 2004-10-07 | Yale University | 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
| GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| US20040224935A1 (en) | 2003-04-07 | 2004-11-11 | Endorecherche, Inc. | Topical antiandrogenic steroids |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| AU2007299010B2 (en) | 2006-09-19 | 2013-01-31 | Solvay Pharmaceuticals Gmbh | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| RU2453554C2 (ru) | 2006-11-30 | 2012-06-20 | Зольвай Фармасьютиклз Гмбх | Замещенные производные эстратриена как ингибиторы 17бета hsd |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| JP2012509351A (ja) | 2008-11-20 | 2012-04-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 有機化合物のフッ素化 |
| US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| US9663549B2 (en) | 2013-06-25 | 2017-05-30 | Forendo Pharma Ltd. | Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase |
| UA126342C2 (uk) | 2017-06-08 | 2022-09-21 | Форендо Фарма Лтд | 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ |
-
2019
- 2019-12-05 SG SG11202105795XA patent/SG11202105795XA/en unknown
- 2019-12-05 CA CA3122049A patent/CA3122049C/en active Active
- 2019-12-05 KR KR1020217018467A patent/KR20210114390A/ko not_active Application Discontinuation
- 2019-12-05 MX MX2021006452A patent/MX2021006452A/es unknown
- 2019-12-05 JP JP2021531553A patent/JP7417608B2/ja active Active
- 2019-12-05 EA EA202191531A patent/EA202191531A1/ru unknown
- 2019-12-05 BR BR112021010598-0A patent/BR112021010598A2/pt not_active Application Discontinuation
- 2019-12-05 AU AU2019393005A patent/AU2019393005B2/en active Active
- 2019-12-05 US US17/299,584 patent/US20220041647A1/en active Pending
- 2019-12-05 WO PCT/FI2019/050874 patent/WO2020115371A1/en active Application Filing
- 2019-12-05 UA UAA202103730A patent/UA126881C2/uk unknown
- 2019-12-05 EP EP19827769.1A patent/EP3891167A1/en active Pending
- 2019-12-05 CN CN201980091146.2A patent/CN113412269A/zh active Pending
-
2021
- 2021-05-31 IL IL283588A patent/IL283588A/en unknown
- 2021-06-03 CL CL2021001468A patent/CL2021001468A1/es unknown
-
2022
- 2022-11-30 AU AU2022279473A patent/AU2022279473A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021010598A2 (pt) | 2021-08-24 |
| AU2019393005A1 (en) | 2021-07-29 |
| KR20210114390A (ko) | 2021-09-23 |
| AU2019393005B2 (en) | 2022-12-15 |
| UA126881C2 (uk) | 2023-02-15 |
| WO2020115371A1 (en) | 2020-06-11 |
| EP3891167A1 (en) | 2021-10-13 |
| AU2022279473A1 (en) | 2023-02-02 |
| CA3122049C (en) | 2023-10-17 |
| IL283588A (en) | 2021-07-29 |
| MX2021006452A (es) | 2021-09-28 |
| EA202191531A1 (ru) | 2021-09-03 |
| US20220041647A1 (en) | 2022-02-10 |
| JP2022510386A (ja) | 2022-01-26 |
| SG11202105795XA (en) | 2021-06-29 |
| CA3122049A1 (en) | 2020-06-11 |
| JP7417608B2 (ja) | 2024-01-18 |
| CN113412269A (zh) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
| ECSP21004787A (es) | Inhibidores de inflamasoma nlrp3 | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| GT201700220A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CO2017003290A2 (es) | Composiciones y kits para desbridación enzimática y metodos de uso de los mismos | |
| CL2019003562A1 (es) | Derivados esteroideos con actividad terapéutica. | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| CL2021001468A1 (es) | Derivados esteroideos con actividad terapéutica | |
| BR112023017040A2 (pt) | Derivados de indolina como inibidores de ddr1 e ddr2 | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento | |
| BR112021019589A2 (pt) | Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |